Table 3.
Summary of subgroup analysis.
| Oxidative stress indicators | Subgroup analysis | Groups | Participants | Random effects SMD (95% CI) | I2 (%) | P for heterogeneity |
|---|---|---|---|---|---|---|
| vs. model group | ||||||
| Super oxide dismutase | low-dose group | 4 | 68 | 3.80 (2.87, 4.73) | 87.80% | P < 0.05 |
| high-dose group | 5 | 143 | 1.04 (0.59, 1.49) | 96.20% | P < 0.05 | |
| Malonicaldehyde | low-dose group | 4 | 68 | −2.26 (−3.00, −1.52) | 91.40% | P < 0.05 |
| high-dose group | 5 | 143 | −1.30 (−1.71, −0.90) | 92.00% | P < 0.05 | |
| Super oxide dismutase | interval <8 weeks group | 3 | 48 | 2.47 (1.49, 3.46) | 93.70% | P < 0.05 |
| Interval ≥ 8 weeks group | 6 | 163 | 1.38 (0.94, 1.83) | 95.90% | P < 0.05 | |
| Malonicaldehyde | interval <8 weeks group | 3 | 48 | −0.97 (−1.80, −0.15) | 94.80% | P < 0.05 |
| Interval ≥ 8 weeks group | 6 | 163 | −1.65 (−2.04, −1.26) | 89.80% | P < 0.05 | |
| vs. Western medicine group | ||||||
| Super oxide dismutase | low-dose group | 4 | 64 | 1.17 (0.52, 1.81) | 93.10% | P < 0.05 |
| high-dose group | 4 | 127 | 0.27 (−0.16, 0.71) | 96.30% | P < 0.05 | |
| Malonicaldehyde | low-dose group | 4 | 64 | −0.92 (−1.47, −0.37) | 84.50% | P < 0.05 |
| high-dose group | 4 | 127 | −0.51 (−0.89, −0.13) | 83.60% | P < 0.05 | |
| Super oxide dismutase | interval <8 weeks group | 3 | 46 | 1.20 (0.49, 1.91) | 86.90% | P < 0.05 |
| Interval ≥ 8 weeks group | 5 | 145 | 0.33 (0.49, 1.91) | 96.3%% | P < 0.05 | |
| Malonicaldehyde | interval <8 weeks group | 3 | 46 | −0.57 (−1.28, 0.14) | 91.80% | P < 0.05 |
| Interval ≥ 8 weeks group | 5 | 145 | −0.66 (−1.01, −0.31) | 78.20% | P < 0.05 |